TRAVERE THERAPEUTICS, INC. Deferred Tax Asset, Interest Carryforward
TRAVERE THERAPEUTICS, INC. (TVTX) had Deferred Tax Asset, Interest Carryforward of $0 as of 2024-12-31, per its 10-K filed 2025-02-21.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetInterestCarryforward · last filed 2025-02-21
- 2024-12-31: Deferred Tax Asset, Interest Carryforward $0.00.
- 2023-12-31: Deferred Tax Asset, Interest Carryforward $1.68M.
- 2022-12-31: Deferred Tax Asset, Interest Carryforward $4.35M.
- 2021-12-31: Deferred Tax Asset, Interest Carryforward $2.80M.
| Period end | Deferred Tax Asset, Interest Carryforward |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-21 |
| 2023-12-31 | $1.68M 10-K · filed 2025-02-21 |
| 2022-12-31 | $4.35M 10-K · filed 2024-02-20 |
| 2021-12-31 | $2.80M 10-K · filed 2023-02-23 |
| 2020-12-31 | $1.66M 10-K · filed 2022-02-24 |
| 2019-12-31 | $345.00K 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |